With 30.02 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.0 whereas the lowest price it dropped to was $4.55. The 52-week range on SONN shows that it touched its highest point at $10.02 and its lowest point at $1.08 during that stretch. It currently has a 1-year price target of $20.00. Beta for the stock currently stands at 0.92.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SONN was up-trending over the past week, with a rise of 322.32%, but this was up by 304.27% over a month. Three-month performance surged to 272.44% while six-month performance rose 223.97%. The stock gained 223.97% in the past year, while it has lost -32.81% so far this year.
Float and Shares Shorts:
At present, 3.17 million SONN shares are outstanding with a float of 3.13 million shares on hand for trading. On 2025-06-13, short shares totaled 60829.0, which was 191.99999 higher than short shares on 1747267200. In addition to Mr. Raghu Rao as the firm’s Interim CEO & Director, Dr. John K. Cini Ph.D. serves as its Chief Scientific Officer & Co-Founder.
Institutional Ownership:
Through their ownership of 0.05242 of SONN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SONN reported revenue of $0.0 and operating income of -$4229420.0. The EBITDA in the recently reported quarter was -$4225522.0 and diluted EPS was -$0.89.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SONN since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SONN analysts setting a high price target of 20.0 and a low target of 20.0, the average target price over the next 12 months is 20.0. Based on these targets, SONN could surge 322.83% to reach the target high and rise by 322.83% to reach the target low. Reaching the average price target will result in a growth of 322.83% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$12.88 being high and -$12.88 being low. For SONN, this leads to a yearly average estimate of -$12.88.
